Oncotelic Therapeutics Inc

Oncotelic Therapeutics Inc exhibits a capital structure with a debt-to-equity ratio of 1.09, indicating a moderate reliance on debt financing. The company's liquidity position is weak, as evidenced by a current ratio of 0.01, suggesting limited ability to meet short-term obligations. The company's cash and equivalents amount to $188,990, which is significantly lower than its long-term debt of $12,893,950, resulting in a negative net cash position.

Profitability metrics for Oncotelic Therapeutics Inc are negative, with a return on equity of -3.45% and a return on assets of -1.36%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The company's operating income and net income are both negative, at -$255,480 and -$408,680, respectively, highlighting ongoing financial challenges.

The company's revenue is not disclosed in the provided data, and there is no information on geographic or segmental revenue distribution. However, the lack of detailed revenue concentration data suggests that Oncotelic Therapeutics Inc may be heavily reliant on a few key products or markets, which could pose a concentration risk if those areas underperform.

Oncotelic Therapeutics Inc is currently experiencing a decline in financial performance, as indicated by negative operating and net income figures. The company's outlook for the current fiscal year is not explicitly provided, but the negative financial results suggest a challenging growth trajectory. The company will need to address its liquidity and profitability issues to achieve sustainable growth.

The company faces several risk factors, including a weak liquidity position and a high debt-to-equity ratio. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag that could impact its financial stability and operational flexibility.

Recent events and filings for Oncotelic Therapeutics Inc are not detailed in the provided data. However, the company's financial snapshot indicates ongoing financial challenges, which may be reflected in recent filings or transcripts. The company will need to address these issues to improve its financial position and investor confidence.

Revenue $70.0k; Operating income +29,6% YoY.

• ▍Revenue $70.0k
• ▍Operating income +29,6% YoY
• ▍Net income −255,1% YoY
• ▍Net margin -11290.1%

Operating income −13,3% YoY; Net income +154,2% YoY.

• ▍Operating income −13,3% YoY
• ▍Net income +154,2% YoY
• ▍Free cash flow +144,8% YoY

Revenue $0.00; Operating income -$8.8M.

• ▍Revenue $0.00
• ▍Operating income -$8.8M